Lupin Limited (NSE:LUPIN) reported a robust operational and financial performance for Q4FY26 and FY26, supported by strong momentum in the North American market, healthy growth across India formulations, and continued expansion in complex generics and specialty products. Despite the strong earnings performance, Lupin shares declined nearly 4% intraday to around ₹2,363 amid broader market weakness and profit booking after a recent rally.
The stock had recently touched fresh highs near ₹2,475 before witnessing sharp selling pressure during the session. Investors appear to be evaluating sustainability of margins following a strong earnings cycle and higher competitive intensity in select products.
Q4 FY26 Financial Performance
Lupin reported Q4FY26 net sales of ₹73,919 million, reflecting strong year-on-year growth of 32.9%. Total revenue stood at ₹74,747 million, while gross profit increased 42.9% YoY to ₹55,403 million.
EBITDA for the quarter surged 68% YoY to ₹21,711 million, with EBITDA margin expanding significantly to 29.4% compared to 23.2% in Q4FY25. Net income jumped 89% year-on-year to ₹14,604 million, supported by improved operating leverage, higher sales contribution from North America, and one-time exceptional gains.
North America remained the key growth engine for the company, with revenue rising 55% YoY to ₹35,145 million during the quarter. India business revenue increased 12% YoY to ₹19,082 million, while EMEA revenue grew 19% YoY. Emerging markets and Latin America also delivered strong growth momentum.
Lupin launched key products including Dapagliflozin tablets (generic Farxiga) and Sugammadex injection (generic Bridion) in the US market during the quarter. The company also received tentative USFDA approvals and continued strengthening compliance across major facilities.
FY26 Financial Performance
For the full financial year FY26, Lupin reported net sales of ₹274,875 million, registering strong growth of 23.9% year-on-year. Total revenue increased 23.1% to ₹279,580 million.
EBITDA rose sharply by 54.6% YoY to ₹81,595 million, while EBITDA margin expanded to 29.7% compared with 23.8% in FY25. Net income surged 62.5% year-on-year to ₹53,329 million, reflecting significant improvement in operational efficiency and profitability.
India formulations business continued outperforming the domestic pharma market, with India Rx business growing 14.5% in Q4FY26 and 10.6% during FY26 against Indian Pharma Market growth of around 9.9%. The company maintained strong positioning across cardiology, respiratory, and diabetes therapies.
Strategy and Outlook
Lupin continued to strengthen its focus on complex generics, biosimilars, inhalation products, injectables, and specialty therapies. The company plans to file more than 15 ANDAs in FY27 while expanding its pipeline across respiratory, injectable, and peptide-based therapies.
Management highlighted that the company aims to derive over 65% of new product launch revenues from complex products by FY31. Lupin also plans to launch more than five biosimilars by FY31 as part of its long-term specialty growth strategy.
During the quarter, Lupin completed the acquisition of VISUfarma B.V., strengthening its specialty pharmaceutical presence in Europe. The company also signed a licensing and supply agreement with Galenicum for Semaglutide across 23 countries, further expanding its GLP-1 portfolio.
In India, Lupin plans to launch over 20 products in FY27 while expanding its chronic therapies and semaglutide-focused divisions. The company also remains focused on digital healthcare platforms, diagnostics expansion, and patient-support programs to deepen healthcare ecosystem engagement.
Technical Summary
Lupin shares corrected sharply after touching fresh highs near ₹2,475, indicating profit booking at elevated levels. The stock remains in a broader uptrend with higher highs and higher lows visible on the chart. Immediate support is placed near ₹2,300, while resistance remains around ₹2,450–₹2,500 amid elevated near-term volatility.
Chart by TradingView
Conclusion
Lupin delivered a strong FY26 performance driven by robust North America growth, expanding margins, and improving operational efficiency. The company’s strategic focus on complex generics, biosimilars, and specialty therapies positions it well for long-term growth. Investors will monitor regulatory developments, pipeline execution, and sustainability of margins going forward.
FAQs
- What drove Lupin’s Q4FY26 earnings growth?
Strong North America sales, margin expansion, key product launches, and improved operational efficiency supported Lupin’s strong quarterly earnings growth. - How did Lupin’s North America business perform?
North America revenue increased 55% year-on-year in Q4FY26, driven by new launches and strong base business momentum. - What is Lupin’s future growth strategy?
Lupin is focusing on complex generics, biosimilars, inhalation products, specialty therapies, and expanding global regulatory approvals.